G0S2, G0/G1 switch 2, 50486

N. diseases: 47; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental 		0.300 Biomarker disease CTD_human Systems level analysis and identification of pathways and networks associated with liver fibrosis. 25380136 2014
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.300 Biomarker group CTD_human Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas. 16316942 2005
CUI: C0024667
Disease: Animal Mammary Neoplasms
Animal Mammary Neoplasms 		0.300 Biomarker phenotype CTD_human Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas. 16316942 2005
CUI: C0024668
Disease: Mammary Neoplasms, Experimental
Mammary Neoplasms, Experimental 		0.300 Biomarker phenotype CTD_human Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas. 16316942 2005
CUI: C0205696
Disease: Anaplastic carcinoma
Anaplastic carcinoma 		0.300 Biomarker disease CTD_human Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas. 16316942 2005
CUI: C0205697
Disease: Carcinoma, Spindle-Cell
Carcinoma, Spindle-Cell 		0.300 Biomarker disease CTD_human Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas. 16316942 2005
CUI: C0205698
Disease: Undifferentiated carcinoma
Undifferentiated carcinoma 		0.300 Biomarker disease CTD_human Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas. 16316942 2005
CUI: C0205699
Disease: Carcinomatosis
Carcinomatosis 		0.300 Biomarker phenotype CTD_human Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas. 16316942 2005
CUI: C1257925
Disease: Mammary Carcinoma, Animal
Mammary Carcinoma, Animal 		0.300 Biomarker disease CTD_human Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas. 16316942 2005
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.040 Biomarker disease BEFREE In this study, we investigated whether G0S2 is regulated by branch of the unfolded protein response (UPR) and contributes to ER stress-induced hepatic steatosis. 31271806 2019
CUI: C0017638
Disease: Glioma
Glioma 		0.040 AlteredExpression disease BEFREE In contrast, overexpression of G0S2 promoted glioma cell radiation resistance. 30953555 2019
CUI: C0017638
Disease: Glioma
Glioma 		0.040 Biomarker disease BEFREE Correction to: Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response. 31311601 2019
CUI: C0017638
Disease: Glioma
Glioma 		0.040 Biomarker disease BEFREE Correction to: Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response. 31358019 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.040 Biomarker disease BEFREE In this study, we investigated whether G0S2 is regulated by branch of the unfolded protein response (UPR) and contributes to ER stress-induced hepatic steatosis. 31271806 2019
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.040 AlteredExpression disease BEFREE These results display a novel molecular mechanism linking Nur77-regulated G0S2 expression to palmitate-induced hepatic steatosis. 29556076 2018
CUI: C0017638
Disease: Glioma
Glioma 		0.040 Biomarker disease BEFREE These results indicate that G0S2 is epigenetically silenced in IDH1-mutant glioma. 30388142 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.040 AlteredExpression disease BEFREE These results display a novel molecular mechanism linking Nur77-regulated G0S2 expression to palmitate-induced hepatic steatosis. 29556076 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.040 Biomarker disease BEFREE In response to LXR agonist T0901317, G0S2 ablation prevented hepatic steatosis and hypertriglyceridemia without affecting the beneficial effects on HDL. 28239648 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.040 Biomarker disease BEFREE The results of the present study indicate that hepatic G0s2 protein may promote hepatic insulin resistance by exacerbating hepatic steatosis. 27624922 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.040 Biomarker disease BEFREE The results of the present study indicate that hepatic G0s2 protein may promote hepatic insulin resistance by exacerbating hepatic steatosis. 27624922 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.040 Biomarker disease BEFREE In response to LXR agonist T0901317, G0S2 ablation prevented hepatic steatosis and hypertriglyceridemia without affecting the beneficial effects on HDL. 28239648 2017
CUI: C0023487
Disease: Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia 		0.030 Biomarker disease BEFREE G0S2 is strongly induced in acute promyelocytic leukemia (APL) cells in response to all trans retinoic acid (ATRA) and we show that inhibition of ATGL in these cells by G0S2 is required for efficacy of ATRA treatment. 26318046 2015
CUI: C0023487
Disease: Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia 		0.030 Biomarker disease BEFREE The G0/G1 switch gene 2 (G0S2) is rapidly induced by all-trans-retinoic acid (RA)-treatment of acute promyelocytic leukemia (APL) and other cells. 23546556 2013
CUI: C0023487
Disease: Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia 		0.030 Biomarker disease BEFREE The functional role of G0S2 in retinoid response of APL warrants further study. 18636162 2008
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.020 AlteredExpression phenotype BEFREE To investigate whether G0S2 affects invasiveness of MDA-MB-231 cells, G0S2 expression was inhibited using siRNA, which led to decreased cell proliferation, migration, and invasion of MDA-MB-231 cells. 31272137 2019